In the methylation data the candidate of interest Kazal-type serine peptidase inhibitor domain 1 (Kazald1) has been shown to demonstrate a shorter overall survival for patients with hypomethylation in gliomas and is suggested to promote progression through invasion and proliferation [23]. Here, KAZALD1 is linked to glioma.